How is DSM creating new opportunities for innovation in the cannabinoid pharmaceuticals market?

Summary

DSM is entering the cannabinoid market to address the growing demand for research on central nervous system disorders and pain management. Cannabinoids are increasingly accepted in consumer markets, and DSM aims to simplify the complex supply chain. Historically used for epilepsy and pain management, ongoing clinical trials explore their potential for Alzheimer's and bipolar disorders. DSM partners with Brains Bioceutical to offer custom-manufactured cannabinoids, prioritizing patient needs and pharmaceutical innovation for better therapies.

Takeaways

• 🌿 DSM sees a significant need for research in central nervous system disorders and pain management, where cannabinoids show high potential.
• 📈 Cannabinoids are gaining popularity in the consumer market, increasing patient comfort in using them as therapy.
• 🔄 DSM aims to simplify the complex cannabinoid supply chain to offer a streamlined solution for customers.
• 🔬 Historically, cannabinoids have been used to treat epilepsy, manage pain and appetite for AIDS and cancer patients.
• 🧪 DSM is interested in ongoing research, with over 150 clinical trials exploring cannabinoids for Alzheimer's, bipolar disorders, and pain management.
• 🤝 DSM is partnering with Brains Bioceutical, a global leader in cannabinoid active ingredients, to innovate and offer a secure supply chain.
• 🏢 Brains Bioceutical is a pioneer in custom manufacturing cannabinoids, enhancing DSM's market entry.
• 🌟 DSM's venture investment and commercial relationship focus on patient-first approaches to pharmaceutical innovation.
• 🌐 Together with Brains, DSM aims to create opportunities for customers to innovate with cannabinoids sustainably.
• 🎵 The partnership is driven by a purpose to provide the best possible therapies to patients through innovation in the pharmaceutical market.

Q & A

Why is now the right time for DSM to enter the cannabinoid active market?

Now is the right time for DSM to enter the cannabinoid active market because there is a growing need for research and treatment of central nervous system disorders and pain management, areas where cannabinoids show high potential.

How are cannabinoids becoming more prevalent in the consumer marketplace?

Cannabinoids are becoming more common in the consumer marketplace due to increasing acceptance and comfort among patients to take them as therapy.

What is the role of DSM in the cannabinoid supply chain?

DSM's role in the cannabinoid supply chain is to simplify its complexity and offer solutions to customers, ensuring a secure and sustainable supply.

What historical uses of cannabinoids are mentioned in the script?

Historically, cannabinoids have been used to treat epilepsy, manage pain and appetite for AIDS and cancer patients.

What is the current research focus on cannabinoids in terms of central nervous system (CNS) diseases?

Currently, there are over 150 active and ongoing clinical trials using cannabinoids, mainly for Alzheimer's, bipolar disorders, and additional pain management treatments.

Why does DSM recognize the importance of innovation in the pharmaceutical market?

DSM recognizes the importance of innovation in the pharmaceutical market to provide patients with the best possible therapies.

Who is DSM partnering with to offer cannabinoid active ingredients?

DSM is partnering with Brains Bioceutical, a global leader and pioneer in the cannabinoid active ingredient space.

What is Brains Bioceutical's capability in the cannabinoid market?

Brains Bioceutical has the capabilities to custom manufacture cannabinoids for DSM's customer base.

What is DSM's purpose and how does this venture investment align with it?

DSM's purpose is to put patients first, and this venture investment and commercial relationship with Brains Bioceutical is focused on providing innovation in the pharmaceutical market for the best patient therapies.

How does DSM aim to create opportunities for customers with its entry into the cannabinoid market?

DSM aims to create opportunities for customers to innovate with cannabinoids and deliver a secure and sustainable supply chain.

What is DSM's vision for the future in terms of cannabinoid therapies?

DSM's vision is to drive innovation in cannabinoid therapies to ensure patients have access to the most effective treatments possible.